Scarica l'app Stockscreener
0.7059
8.61%
-0.0665
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FGEN Giù?
Forum
Previsione
Precedente Chiudi:
$0.7724
Aprire:
$0.704
Volume 24 ore:
9.37M
Relative Volume:
3.03
Capitalizzazione di mercato:
$71.13M
Reddito:
$147.75M
Utile/perdita netta:
$-284.23M
Rapporto P/E:
-0.2409
EPS:
-2.93
Flusso di cassa netto:
$-317.54M
1 W Prestazione:
+27.30%
1M Prestazione:
+33.16%
6M Prestazione:
+75.99%
1 anno Prestazione:
-58.84%
Intervallo 1D:
$0.6512
$0.7872
Intervallo di 1 settimana:
$0.54
$0.8775
Portata 52W:
$0.18
$2.80
Fibrogen Inc Stock (FGEN) Company Profile
Nome
Fibrogen Inc
Settore
Industria
Telefono
415-978-1200
Indirizzo
350 BAY STREET, SAN FRANCISCO, CA
Confronta FGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.7059 | 71.13M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Downgrade | Stifel | Buy → Hold |
| 2023-06-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Aggiornamento | Stifel | Hold → Buy |
| 2023-01-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-09-22 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-07-16 | Downgrade | Stifel | Buy → Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Downgrade | Mizuho | Buy → Neutral |
| 2021-03-31 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-03-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-26 | Iniziato | Raymond James | Underperform |
| 2020-07-10 | Ripresa | Stifel | Buy |
| 2020-05-01 | Iniziato | Cowen | Market Perform |
| 2020-04-27 | Iniziato | BofA/Merrill | Neutral |
| 2019-05-29 | Ripresa | Goldman | Neutral |
| 2019-05-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Iniziato | Piper Jaffray | Neutral |
| 2019-02-11 | Ripresa | Stifel | Buy |
| 2018-12-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2017-08-08 | Reiterato | Leerink Partners | Outperform |
| 2017-08-08 | Reiterato | Stifel | Buy |
| 2017-07-21 | Downgrade | Goldman | Buy → Neutral |
| 2017-07-11 | Iniziato | Jefferies | Buy |
| 2016-02-11 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
| 2015-12-04 | Iniziato | Citigroup | Buy |
| 2015-09-23 | Iniziato | Lake Street | Hold |
| 2015-07-29 | Iniziato | Citigroup | Buy |
| 2015-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2014-12-09 | Iniziato | Stifel | Buy |
Mostra tutto
Fibrogen Inc Borsa (FGEN) Ultime notizie
FibroGen sells China biz to AstraZeneca for $160 M - BSA bureau
FibroGen sells China unit to AstraZeneca for $160 million - MSN
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal - MSN
Moody's Lifts AstraZeneca's Ratings, Revises Outlook to Stable -February 21, 2025 at 11:51 am EST - Marketscreener.com
FibroGen stock holds $10 target amid China unit sale By Investing.com - Investing.com South Africa
FibroGen stock holds $10 target amid China unit sale - Investing.com
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise - Simply Wall St
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - MarketBeat
This Small Cap Soared Following Subsidiary Sale Announcement Worth $160M - The Globe and Mail
FibroGen to sell China business, extend cash runway to focus on cancer drugs - San Francisco Business Times
FibroGen sells China unit to AstraZeneca for $160m - Yahoo Finance
FibroGen (FGEN) to Release Earnings on Monday - MarketBeat
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga
FibroGen sells China business to AstraZeneca - The Pharma Letter
AstraZeneca deepens China presence with FibroGen deal - BioPharma Dive
AstraZeneca to buy FibroGen's China unit for $160 million - MSN
FibroGen stock soars on China unit sale - Investing.com
FibroGen Sells Subsidiary to AstraZeneca for $160M - TipRanks
FibroGen soars on $160 mln China unit sale to AstraZeneca - TradingView
AstraZeneca to buy FibroGen's China unit for $160 million -February 20, 2025 at 07:04 am EST - Marketscreener.com
FibroGen Sells China Unit to AstraZeneca in $160 Million DealNews and Statistics - IndexBox, Inc.
FibroGen sells China unit to AstraZeneca in deal worth $160 million By Reuters - Investing.com
FibroGen sells China unit to AstraZeneca in deal worth $160 million -February 20, 2025 at 06:40 am EST - Marketscreener.com
FibroGen sells China unit to AstraZeneca for $160 million (FGEN:NASDAQ) - Seeking Alpha
FibroGen Announces Sale of China Subsidiary to AstraZeneca for Approximately $160 Million - Nasdaq
FibroGen sells China unit to AstraZeneca in deal worth $160 million - Yahoo Finance UK
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million - GlobeNewswire
Inside FibroGen's $160M China Exit: Strategic Pivot or Cash Grab? - StockTitan
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 5.2% in January - Defense World
FibroGen Inc: Weathering Stock Market Storms with 51.09M Market Cap - The InvestChronicle
Trading Day Triumph: FibroGen Inc (FGEN) Ends at 0.46, a -2.61 Surge/Plunge - The Dwinnex
FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com - Defense World
JPMorgan Chase & Co. Has $668,000 Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Assenagon Asset Management S.A. Sells 415,812 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen (NASDAQ:FGEN) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
FibroGen Inc (NASDAQ: FGEN) Is Down -5.77% – Can It Revive? - Stocks Register
FibroGen, Inc. (NASDAQ:FGEN) Shares Purchased by Geode Capital Management LLC - Defense World
Perspective Therapeutics Appoints FibroGen Veteran Juan Graham as New CFO to Drive Growth Strategy - StockTitan
State Street Corp Lowers Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World
FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
FibroGen (NASDAQ:FGEN) Coverage Initiated at StockNews.com - MarketBeat
Court of Chancery Applies Well-Settled Principles To Dismiss Malone/Caremark ‘Hybrid’ Claims - JD Supra
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com - Defense World
Recent Investment Analysts’ Ratings Updates for FibroGen (FGEN) - Defense World
Fmr LLC Boosts Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
HC Wainwright Comments on FibroGen FY2024 Earnings - Defense World
HC Wainwright Upgrades FibroGen (NASDAQ:FGEN) to Strong-Buy - Defense World
HC Wainwright Estimates FibroGen FY2026 Earnings - Defense World
Fibrogen Inc Azioni (FGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fibrogen Inc Azioni (FGEN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Mar 07 '24 |
Buy |
1.91 |
50,000 |
95,470 |
470,178 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):